Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and growth potential. Learn why BMY stock is a solid ...

KarXT received FDA approval in September, becoming the first antipsychotic drug to treat schizophrenia that targets cholinergic receptors rather than dopamine receptors, which are the primary target ...

Prime Target kicks off with a fascinating premise: Edward Brooks (Leo Woodall) is on the brink of unraveling the mathematical secrets that safeguard every computer system in the world. The ...

Xanomeline and trospium chloride (KarXT), a novel M1/M4 muscarinic receptor agonist, significantly improves cognitive performance among patients with schizophrenia who have baseline cognitive ...

“KarXT is the first new class of treatment for ... as compared to current antipsychotic medicines, which mostly target dopamine or serotonin receptors. Zai Lab has an exclusive license from ...

"In clinical trials, KarXT demonstrated statistically significant reductions of schizophrenia symptoms along with a tolerable safety profile. If approved, KarXT has the potential to redefine the ...

“KarXT is the first new class of treatment for ... as compared to current antipsychotic medicines, which mostly target dopamine or serotonin receptors. Schizophrenia is a persistent and often ...

January 17, 2025--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) ...

Zai Lab (ZLAB) announced that China’s National Medical Products Administration, NMPA, has accepted the New Drug Application, NDA, for KarXT for the treatment of schizophrenia in adults.